APLS Apellis Pharmaceuticals Inc

$20.33

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/17/2025

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.

Website: https://apellis.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1492422
Address
6400 WESTWIND WAY, SUITE A, CRESTWOOD, KY, US
Valuation
Market Cap
$2.28B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
10.00
Performance
EPS
$-1.60
Dividend Yield
—
Profit Margin
-25.30%
ROE
-93.50%
Technicals
50D MA
$24.37
200D MA
$30.88
52W High
$50.98
52W Low
$17.48
Fundamentals
Shares Outstanding
126M
Target Price
$42.35
Beta
0.84

APLS EPS Estimates vs Actual

● Estimated
● Actual

APLS News & Sentiment

Nov 12, 2025 • Benzinga NEUTRAL
What's Going On With Apellis Pharma Stock Wednesday? - Apellis Pharmaceuticals ( NASDAQ:APLS )
On Wednesday, Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with Syfovre ( pegcetacoplan injection ) for geographic atrophy ( GA ) secondary to age-related macular degeneration ( AMD ...
Nov 06, 2025 • Benzinga SOMEWHAT-BULLISH
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Apellis Pharmaceuticals ( NASDAQ:APLS ) , Abivax ( NASDAQ:ABVX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Nov 05, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
WALTHAM, Mass., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET.
Oct 31, 2025 • Zacks Commentary NEUTRAL
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
Oct 30, 2025 • Zacks Commentary NEUTRAL
Apellis Pharmaceuticals, Inc. ( APLS ) Q3 Earnings and Revenues Top Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +62.14% and +25.22%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 30, 2025 • GlobeNewswire NEUTRAL
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
WALTHAM, Mass., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its third quarter 2025 financial results and business highlights.
Sentiment Snapshot

Average Sentiment Score:

0.136
50 articles with scored sentiment

Overall Sentiment:

Neutral

APLS Reported Earnings

Jul 31, 2025
Jun 30, 2025 (Pre market)
0.15 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.48
  • Whisper: —
  • Surprise %: 31.2%
May 07, 2025
Mar 31, 2025 (Pre market)
-0.2 Surprise
  • Reported EPS: $-0.74
  • Estimate: $-0.54
  • Whisper: —
  • Surprise %: -37.0%
Feb 28, 2025
Dec 31, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.29
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 27.8%
Nov 05, 2024
Sep 30, 2024 (Pre market)
-0.16 Surprise
  • Reported EPS: $-0.46
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: -54.1%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.32
  • Whisper: —
  • Surprise %: 12.5%
May 07, 2024
Mar 31, 2024 (Pre market)
0.05 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.47
  • Whisper: —
  • Surprise %: 10.6%
Feb 27, 2024
Dec 31, 2023 (Pre market)
-0.04 Surprise
  • Reported EPS: $-0.73
  • Estimate: $-0.69
  • Whisper: —
  • Surprise %: -5.8%
Nov 01, 2023
Sep 30, 2023 (Pre market)
-0.31 Surprise
  • Reported EPS: $-1.17
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -36.0%
Jul 31, 2023
Jun 30, 2023 (Pre market)
0.3 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-1.32
  • Whisper: —
  • Surprise %: 22.7%

Financials